![]() |
|
|
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas
The active site topology of heterologously expressed CYP3A4 purified from an Escherichia coli expression system was examined using phenyldiazene. Incubation of CYP3A4 with phenyldiazene and subsequent oxidation yielded all four potential N-phenylprotoporphyrin IX regioisomers derived from attack on an available nitrogen atom in pyrrole rings B, A, C, or D (NB:NA:NC:ND = 6:73:7: 13). Further study using 28 active site mutants showed that substitution of residues closer to the heme, Ala-305, Thr-309, or Ala-370, with a larger residue caused the most drastic changes in regioisomer formation, which reflected the location of each amino acid residue replaced in a CYP3A4 homology model. Previous studies have suggested a conformational change in CYP3A4 upon binding of NADPH-cytochrome P450 reductase (CPR) or cytochrome b5 (b5). Therefore, regioisomer formation was also compared in the absence of redox partners and in the presence of CPR, b5, or both. Formation of all four regioisomers in CYP3A4 wild type, particularly the minor ones, was reduced in the presence of b5. CPR also greatly decreased the three minor isomers but increased the major isomer significantly. The presence of b5 and CPR restored minor isomer formation and suppressed the enhancement of NA formation caused by CPR alone. Interestingly, the effects of the redox partners differed among representative active site mutants. In particular, the increase in NC upon substitution of Ala-370 with Phe was significantly reversed in the presence of redox partners, strongly suggesting that a conformational change occurs around pyrrole ring C due to protein-protein interactions between CYP3A4 and CPR or b5.
This article has been cited by other articles:
![]() |
N. N. Bumpus and P. F. Hollenberg Investigation of the Mechanisms Underlying the Differential Effects of the K262R Mutation of P450 2B6 on Catalytic Activity Mol. Pharmacol., October 1, 2008; 74(4): 990 - 999. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kumar, H. Liu, and J. R. Halpert Engineering of Cytochrome P450 3A4 for Enhanced Peroxide-Mediated Substrate Oxidation Using Directed Evolution and Site-Directed Mutagenesis Drug Metab. Dispos., December 1, 2006; 34(12): 1958 - 1965. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sridar, Y. Kobayashi, H. Brevig, U. M. Kent, S. G. Puppali, J. M. Rimoldi, and P. F. Hollenberg Synthesis of Substituted Phenyl Diaziridines and Characterization as Mechanism-Based Inactivators of Human Cytochrome P450 2B6 Drug Metab. Dispos., November 1, 2006; 34(11): 1849 - 1855. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Hummel, T. S. Tracy, J. M. Hutzler, J. L. Wahlstrom, Y. Zhou, and D. A. Rock Influence of Fluorescent Probe Size and Cytochrome b5 on Drug-Drug Interactions in CYP2C9 J Biomol Screen, April 1, 2006; 11(3): 303 - 309. [Abstract] [PDF] |
||||
![]() |
M K Akhtar, S L Kelly, and M A Kaderbhai Cytochrome b5 modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis J. Endocrinol., November 1, 2005; 187(2): 267 - 274. [Abstract] [Full Text] [PDF] |
||||